HNGZY (Hangzhou Tigermed Consulting Co) EV-to-Revenue : 4.56 (As of May. 12, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hangzhou Tigermed Consulting Co's enterprise value is $4,118.0 Mil. Hangzhou Tigermed Consulting Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $902.3 Mil. Therefore, Hangzhou Tigermed Consulting Co's EV-to-Revenue for today is 4.56.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's EV-to-Revenue or its related term are showing as below:

HNGZY' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.41 Med: 13.07 Max: 49.37
Current: 6.45

During the past 13 years, the highest EV-to-Revenue of Hangzhou Tigermed Consulting Co was 49.37. The lowest was 4.41. And the median was 13.07.

HNGZY's EV-to-Revenue is ranked worse than
75.12% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.73 vs HNGZY: 6.45

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-12), Hangzhou Tigermed Consulting Co's stock price is $4.00. Hangzhou Tigermed Consulting Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.05. Therefore, Hangzhou Tigermed Consulting Co's PS Ratio for today is 3.82.

Hangzhou Tigermed Consulting Co EV-to-Revenue Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co EV-to-Revenue Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

41.66

20.45

12.62

6.41

7.78

Hangzhou Tigermed Consulting Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															6.29	6.58	9.58	7.78	7.48

Competitive Comparison of Hangzhou Tigermed Consulting Co's EV-to-Revenue

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Tigermed Consulting Co's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Hangzhou Tigermed Consulting Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hangzhou Tigermed Consulting Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	4117.960	/	902.3
	=	4.56

Hangzhou Tigermed Consulting Co's current Enterprise Value is $4,118.0 Mil.
Hangzhou Tigermed Consulting Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $902.3 Mil.

Hangzhou Tigermed Consulting Co (OTCPK:HNGZY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hangzhou Tigermed Consulting Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.00	/	1.048
	=	3.82

Hangzhou Tigermed Consulting Co's share price for today is $4.00.
Hangzhou Tigermed Consulting Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05.

Hangzhou Tigermed Consulting Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (OTCPK:HNGZY) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

03347:Hong Kong 5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.